Dermatology

Gastrointestinal Cancers

Questions discussed in this category

Will you offer patients urea-based creams or topical diclofenac for hand-foot prophylaxis with capecitabine after the D-TORCH trial results?

D-TORCH compared topical diclofenac to placebo.

4 Answers available

What advice do you have for the management of nail toxicity associated with pemigatinib and other FGFR inhibitors?

1 Answer available

Would the diagnosis of skin-only morphea (localized scleroderma) alter treatment recommendations for localized anal cancer?

1 Answer available

Papers discussed in this category

Oncologist, 2020 Oct 28

Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines.

JAMA Dermatol, 2017 Jul 01

Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2024 Feb 27

Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.

Related Topics in Dermatology